Business - Monitor   

USFDA nod for Orchid's Cephalexin

MUMBAI: Orchid Chemicals & Pharmaceuticals has informed the National Stock Exchange that its flagship product, Cephalexin, has been formally approved by the USFDA. Pursuant to the successful USFDA audit in November last year, Orchid has now received a formal approval from the USFDA authorities, said a company release.

Printer friendly page  
Send this article to Friends by E-Mail

Business

News: Front Page | National | Southern States | Other States | International | Opinion | Business | Sport | Miscellaneous |
Advts: Classifieds | Employment | Obituary |

Stories in this Section

• Polaris ready to face bank's charge in Singapore court
• Software sector wants continuation of tax incentives
• Sugar mills seek sops
• IDBI Bank's unique home loan scheme
• Gold spend up 8 p.c.
• RBI asks banks to disclose consolidated financial statements
• Biometrics, smart card help curb cyber crime
• SecureSynergy's initiative
• GM's tech centre in Bangalore
• Canara Bank to raise Rs. 500 cr. as Tier II capital
• Parry Agro's open offer
• Sensex drops 40 points
• Exchange rates
• Stock Market Index
• Bullion rates
• Satyam Computer partners Correlate
• Moser Baer's pact with Imation
• SoCrates sets up India centre
• Citrix joins hands with Wipro Infotech
• USFDA nod for Orchid's Cephalexin
• PNB revises FCNR(B) rates
• BHEL bags TNEB order
• New CEO for Netkraft

Copyright © 2003, The Hindu. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu